Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2017 | Pages:
96 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Liver Cirrhosis - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Cirrhosis - Pipeline Review, H1 2017, provides an overview of the Liver Cirrhosis (Gastrointestinal) pipeline landscape. Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver which affects the normal flow of blood through the liver. Symptoms include loss of appetite, itchy skin, weight loss, tiredness and weakness and nausea. Treatment includes liver transplant surgery. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Cirrhosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Liver Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Liver Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 3, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Liver Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Cirrhosis (Gastrointestinal). - The pipeline guide reviews pipeline therapeutics for Liver Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Liver Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Liver Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Liver Cirrhosis (Gastrointestinal) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Liver Cirrhosis (Gastrointestinal). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Liver Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Liver Cirrhosis - Overview Liver Cirrhosis - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Liver Cirrhosis - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Liver Cirrhosis - Companies Involved in Therapeutics Development Conatus Pharmaceuticals Inc Galectin Therapeutics Inc Gilead Sciences Inc Human Stem Cells Institute International Stem Cell Corp Ocera Therapeutics Inc Pharmicell Co Ltd S-Evans Biosciences Inc Stelic Institute & Co Inc Stempeutics Research Pvt Ltd VESSL Therapeutics Ltd Liver Cirrhosis - Drug Profiles BCD-800 - Drug Profile Product Description Mechanism Of Action R&D Progress Cell Therapy for Liver Cirrhosis - Drug Profile Product Description Mechanism Of Action R&D Progress Cellgram-LC - Drug Profile Product Description Mechanism Of Action R&D Progress emricasan - Drug Profile Product Description Mechanism Of Action R&D Progress Gemacell - Drug Profile Product Description Mechanism Of Action R&D Progress GMCT-01 - Drug Profile Product Description Mechanism Of Action R&D Progress GRMD-02 - Drug Profile Product Description Mechanism Of Action R&D Progress GXHPC-1 - Drug Profile Product Description Mechanism Of Action R&D Progress ND-654 - Drug Profile Product Description Mechanism Of Action R&D Progress ornithine phenylacetate - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit NLRP3 for Liver Cirrhosis and Non-Alcoholic Steatohepatitis - Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy for Alpha-Antitrypsin Deficiency, Crigler-Najjar Syndrome and Liver Cirrhosis - Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy for Articular Cartilage Defect, Cerebral Hemorrhage, Liver Cirrhosis, Pneumoconiosis and Rheumatoid Arthritis - Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy for Liver Cirrhosis and Rheumatoid Arthritis - Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis - Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy for Metabolic, Gastrointestinal, Multiple Organ Failure and Respiratory Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Stempeucel - Drug Profile Product Description Mechanism Of Action R&D Progress STNM-04 - Drug Profile Product Description Mechanism Of Action R&D Progress Liver Cirrhosis - Dormant Projects Liver Cirrhosis - Discontinued Products Liver Cirrhosis - Product Development Milestones Featured News & Press Releases Nov 14, 2016: Conatus Announces Poster Presentations at AASLD Annual Meeting Nov 03, 2016: Conatus Initiates Phase 2b ENCORE-PH Clinical Trial of Emricasan in Patients with NASH Cirrhosis May 04, 2016: Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial Apr 18, 2016: Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data Mar 30, 2016: Conatus Pharmaceuticals Announces Late Breaker Oral Presentation on Emricasan at EASL Meeting Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial Nov 16, 2015: Conatus Pharmaceuticals Announces Late-Breaking Oral Presentation at AASLD Annual Meeting Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting Oct 01, 2015: Conatus Pharmaceuticals Announces Acceptance of Abstracts for AASLD Annual Meeting Jun 25, 2015: Conatus Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial of Emricasan Confirming Activity of Relevant Mechanisms and Opportunity for Histological Improvement May 14, 2015: Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Liver Cirrhosis, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Liver Cirrhosis - Pipeline by Conatus Pharmaceuticals Inc, H1 2017 Liver Cirrhosis - Pipeline by Galectin Therapeutics Inc, H1 2017 Liver Cirrhosis - Pipeline by Gilead Sciences Inc, H1 2017 Liver Cirrhosis - Pipeline by Human Stem Cells Institute, H1 2017 Liver Cirrhosis - Pipeline by International Stem Cell Corp, H1 2017 Liver Cirrhosis - Pipeline by Ocera Therapeutics Inc, H1 2017 Liver Cirrhosis - Pipeline by Pharmicell Co Ltd, H1 2017 Liver Cirrhosis - Pipeline by S-Evans Biosciences Inc, H1 2017 Liver Cirrhosis - Pipeline by Stelic Institute & Co Inc, H1 2017 Liver Cirrhosis - Pipeline by Stempeutics Research Pvt Ltd, H1 2017 Liver Cirrhosis - Pipeline by VESSL Therapeutics Ltd, H1 2017 Liver Cirrhosis - Dormant Projects, H1 2017 Liver Cirrhosis - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
